A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors

被引：0
|
作者：
Gupta, Sudeep
Jain, Minish Mahendra
Maru, Anish
Nag, Shona Milon
Somani, Naresh
Mehta, Ajay O.
Kulkarni, Sujay
Acharya, Shivani Anil
Dhobe, Poornima
Jadhav, Nitin
机构：
[1] Tata Mem Hosp, Bombay, Maharashtra, India
[2] Ruby Hall Clin, Pune, Maharashtra, India
[3] SEAROC Canc Ctr, Jaipur, Rajasthan, India
[4] Jehangir Clin Trials Dev Ctr, Pune, Maharashtra, India
[5] Bhagwan Mahaveer Canc Hosp & Res Ctr, Jaipur, Rajasthan, India
[6] Cent India Canc Res Inst, Nagpur, Maharashtra, India
[7] Piramal Healthcare Ltd, Bombay, Maharashtra, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors
    Kristeleit, R.
    Calvert, H.
    Arkenau, H.
    Olmos, D.
    Adam, J.
    Plummer, E. R.
    Lock, V.
    Squires, M.
    Fazal, L.
    Judson, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy
    White, JD
    Cassidy, J
    Twelves, C
    Benson, C
    Pacey, S
    Judson, I
    McGrath, H
    Rose, F
    Frenz, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 205S - 205S
  • [23] Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
    Flaherty, Keith T.
    LoRusso, Patricia M.
    DeMichele, Angela
    Abramson, Vandana G.
    Courtney, Rachel
    Randolph, Sophia S.
    Shaik, M. Naveed
    Wilner, Keith D.
    O'Dwyer, Peter J.
    Schwartz, Gary K.
    CLINICAL CANCER RESEARCH, 2012, 18 (02) : 568 - 576
  • [24] Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
    Senderowicz, AM
    Headlee, D
    Stinson, SF
    Lush, RM
    Kalil, N
    Villalba, L
    Hill, K
    Steinberg, SM
    Figg, WD
    Tompkins, A
    Arbuck, SG
    Sausville, EA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 2986 - 2999
  • [25] A phase I and pharmalogical study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327, administered to subjects with advanced or refractory solid tumors
    Konings, Inge R.
    de Jonge, Maja J.
    Burger, Herman
    van der Gaast, Ate
    van Bijsterveld, Ludy E. C.
    Winkler, Hans
    Hellemans, Peter
    Eskens, Ferry A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [26] Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
    Tamura, Kenji
    Mukai, Hirofumi
    Naito, Yoichi
    Yonemori, Kan
    Kodaira, Makoto
    Tanabe, Yuko
    Yamamoto, Noboru
    Osera, Shozo
    Sasaki, Masaoki
    Mori, Yuko
    Hashigaki, Satoshi
    Nagasawa, Takashi
    Umeyama, Yoshiko
    Yoshino, Takayuki
    CANCER SCIENCE, 2016, 107 (06) : 755 - 763
  • [27] A phase I study of R547, a novel cyclin dependent kinase inhibitor, in patients (pts) with advanced cancer: preliminary results
    Camidge, D. R.
    Eckhardt, S. G.
    Tan, A.
    Frenette, G.
    Diab, S.
    Depinto, W.
    Grippo, J. F.
    DeMario, M.
    Mikulski, S.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2006, 4 (12): : 89 - 89
  • [28] Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
    Monica M Mita
    Alain C Mita
    Jennifer L Moseley
    Jennifer Poon
    Karen A Small
    Ying-Ming Jou
    Paul Kirschmeier
    Da Zhang
    Yali Zhu
    Paul Statkevich
    Kamelesh K Sankhala
    John Sarantopoulos
    James M Cleary
    Lucian R Chirieac
    Scott J Rodig
    Rajat Bannerji
    Geoffrey I Shapiro
    British Journal of Cancer, 2017, 117 : 1258 - 1268
  • [29] Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
    Mita, Monica M.
    Mita, Alain C.
    Moseley, Jennifer L.
    Poon, Jennifer
    Small, Karen A.
    Jou, Ying-Ming
    Kirschmeier, Paul
    Zhang, Da
    Zhu, Yali
    Statkevich, Paul
    Sankhala, Kamelesh K.
    Sarantopoulos, John
    Cleary, James M.
    Chirieac, Lucian R.
    Rodig, Scott J.
    Bannerji, Rajat
    Shapiro, Geoffrey I.
    BRITISH JOURNAL OF CANCER, 2017, 117 (09) : 1258 - 1268
  • [30] A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Schwartz, G. K.
    Robertson, S.
    Shen, A.
    Wang, E.
    Pace, L.
    Dials, H.
    Mendelson, D.
    Shannon, P.
    Gordon, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345